Alexey V. Zakharov

Alexey V. Zakharov

Auto-generated profile, based on publicly available information

Alexey V. Zakharov

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WJWengong Jin
Wengong Jin
JSJonathan M. Stokes
Jonathan M. Stokes
RERichard Eastman
Richard Eastman
ZIZina Itkin
Zina Itkin
AZAlexey V. Zakharov
Alexey V. Zakharov
RBRegina Barzilay
Regina Barzilay
Significance: COVID-19 has caused more than 2.5 million deaths worldwide. It is imperative that we develop therapies that can mitigate the effect of the disease. While searching for individual drugs for this purpose has been met with difficulties, synergistic drug combinations offer a promising alternative. However, the lack of high-quality training data pertaining to drug combinations makes it challenging to use existing machine learning methods for effective novel combination prediction tasks. Our proposed approach addresses this challenge by leveraging additional readily available data, such as drug−target interactions, thus enabling an effective in silico search for synergistic combinations against SARS-CoV-2.

3 February 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
SJSankalp Jain
Sankalp Jain
VSVishal B. Siramshetty
Vishal B. Siramshetty
VAVinicius Alves
Vinicius Alves
EMEugene Muratov
Eugene Muratov
NKNicole Kleinstreuer
Nicole Kleinstreuer
AZAlexey V. Zakharov
Alexey V. Zakharov

1 February 2021 in Molecular Therapy
Verified
Journal Article
Open access
TBTesia Bobrowski
Tesia Bobrowski
LCLu Chen
Lu Chen
RERichard T. Eastman
Richard T. Eastman
ZIZina Itkin
Zina Itkin
PSPaul Shinn
Paul Shinn
EMEugene Muratov
Eugene Muratov
Antiviral drug development for coronavirus disease 2019 (COVID-19) is occurring at an unprecedented pace, yet there are still limited therapeutic options for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2, thus generating better antiviral efficacy. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Sixteen synergistic and eight antagonistic combinations were identified; among 16 synergistic cases, combinations of the US Food and Drug Administration (FDA)-approved drug nitazoxanide with remdesivir, amodiaquine, or umifenovir were most notable, all exhibiting significant synergy against SARS-CoV-2 in a cell model. However, the combination of remdesivir and lysosomotropic drugs, such as hydroxychloroquine, demonstrated strong antagonism. Overall, these results highlight the utility of drug repurposing and preclinical testing of drug combinations for discovering potential therapies to treat COVID-19.

25 October 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
AZAlexey V. Zakharov
Alexey V. Zakharov
TZTongan Zhao
Tongan Zhao
DNDac-Trung Nguyen
Dac-Trung Nguyen
TPTyler Peryea
Tyler Peryea
TSTimothy Sheils
Timothy Sheils
ASAnton Simeonov
Anton Simeonov

5 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKyle R. Brimacombe
Kyle R. Brimacombe
TZTongan Zhao
Tongan Zhao
RERichard Eastman
Richard Eastman
XHXin Hu
Xin Hu
KWKe Wang
Ke Wang
MSMin Shen
Min Shen
The National Center for Advancing Translational Sciences (NCATS) has developed an online open science platform – named the NCATS OpenData Portal (ODP) – for quickly and freely sharing complete NCATS translational datasets via an open-access, user-friendly interface. This paper describes the establishment of the ODP, initially deployed during the COVID-19 crisis, and provides a detailed analysis of COVID-19 drug repurposing screening datasets that served as the first large-scale use case for the platform. Over 10,000 compounds were tested across 17 quantitative high-throughput assays, covering a wide spectrum of the SARS-CoV-2 life cycle. In total, over 87,000 concentration-response curves and 426,000 data points were made publicly available on ODP in near real-time, enabling immediate access to complete datasets. The resource is flexible in accommodating various types and structures of data, and it has already expanded since its launch to host additional datasets for COVID-19, other viruses of pandemic potential, and beyond. The OpenData Portal has been designed as a scalable platform for real-time data sharing across drug discovery campaigns, regardless of disease area, with the overarching goal of accelerating discovery at NCATS, the NIH, and the greater scientific community.

18 October 2012 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
AZAlexey V. Zakharov
Alexey V. Zakharov
ALAlexey Lagunin
Alexey Lagunin
DFDmitry Filimonov
Dmitry Filimonov
Vladimir Vassilievich PoroikovVladimir Vassilievich Poroikov
Vladimir Vassilievich Poroikov